In the broader study population, 75% of molecular tumor board recommendations were influenced by TuPro data. Patients receiving TuPro-guided treatment achieved a 60% objective response rate (ORR) in the standard-of-care (SOC) group and a 38% ORR in the beyond-SOC group. Across all groups, disease control was 61%, and the median PFS reached 6.04 months.
The prospective study included 116 melanoma patients and leveraged single-cell sequencing, spatial proteomics, imaging mass cytometry, and drug phenotyping to profile tumors with over 43,000 markers per sample — all within a clinically feasible 4-week turnaround. These data were translated into clinical recommendations via a multi-institutional molecular tumor board.
“This study demonstrates the feasibility of using advanced multiomics approaches, including spatial proteomics, to guide therapy decisions in late-stage melanoma — one of the most aggressive and treatment-resistant cancers — with a reproducible patient benefit,” said Dr. Stéphane Chevrier, CSO and co-founder of Navignostics, and contributor the TuPro study. “This is a major step toward pan-cancer diagnostics. By providing a comprehensive view of the tumor biology, the approach could eventually identify features that are predictive for treatments across cancer indications”
Navignostics’ technology was instrumental in delivering multi-dimensional insights at the cellular and molecular level. Navignostics’ diagnostics are currently available for early research access for colorectal and lung cancer in Switzerland, with broader distribution via partner pathology labs scheduled for 2026. Expansion into melanoma and pan-cancer applications is underway.
Full study: Nature Medicine
Navignostics contact: media@navignostics.com
Media kit linked here
